Eli Lilly Acquires 4E Therapeutics to Enhance Non-Opioid Pain Management Advances
In a significant move for pain management innovation, Eli Lilly and Company has acquired 4E Therapeutics, a pioneering neuroscience firm based in Austin, Texas. This acquisition marks a strategic alliance aimed at advancing non-opioid solutions for those suffering from chronic pain. 4E Therapeutics specializes in the development of next-generation treatments that target the underlying neurological mechanisms of chronic pain, employing a pipeline of orally available MNK inhibitors.
4E's leading compound, known as 4ET1103, is notable as it is the first MNK inhibitor developed specifically for pain treatment to progress into human clinical trials. Initial studies have shown 4ET1103 to possess a promising safety profile during its Phase 1 assessments. The innovative approach of 4E focuses on disrupting the MNK-eIF4E signaling pathway in peripheral sensory neurons, aiming to provide effective pain relief without triggering the central nervous system effects that many existing medications do.
Joseph Price, the co-founder and president of 4E Therapeutics, expressed his enthusiasm regarding the acquisition, stating, "We founded 4E Therapeutics with a simple but ambitious goal: to create non-opioid therapies that directly address the neurological causes of pain. Lilly’s commitment to combating chronic pain, coupled with its vast resources and global reach, makes it the perfect partner to bring this vision to fruition."
The sentiment is echoed by Dr. Theodore Price, another co-founder of 4E Therapeutics and a distinguished figure in pain research. Commenting on the evolution of their scientific breakthroughs into viable treatments, he noted, "Witnessing our extensive research on the molecular mechanisms behind chronic pain transition from basic studies to clinical applications, now integrated within Lilly’s development pipeline, is a thrilling opportunity to expedite access to new therapies for patients." This highlights the synergy of their combined efforts to tackle the multifaceted challenges of chronic pain treatments.
Although the financial terms of this transaction remain undisclosed, the partnership is believed to be a valuable step forward for both companies. 4E Therapeutics was advised by Aquilo Partners LP during the acquisition process, while Wilson Sonsini Goodrich & Rosati provided legal support.
Founded on the principles of advanced neuroscience, 4E Therapeutics aims to redefine the landscape of pain management by developing non-addictive therapies. Their focus ranges across various pain-related conditions, such as neuropathic and acute pain, through groundbreaking mechanisms that seek to interrupt pain signaling at its core. The company’s journey in medicinal chemistry and drug development has been notably led by Vice President of Drug Development, James Sahn, while T. Craig Benson, a serial entrepreneur in biotechnology, has guided 4E from its inception as CEO.
With the acquisition now finalized, both Lilly and 4E Therapeutics are poised to harness their combined expertise and resources to expedite the development of innovative therapies, ultimately benefitting countless individuals grappling with chronic pain conditions.
4E's leading compound, known as 4ET1103, is notable as it is the first MNK inhibitor developed specifically for pain treatment to progress into human clinical trials. Initial studies have shown 4ET1103 to possess a promising safety profile during its Phase 1 assessments. The innovative approach of 4E focuses on disrupting the MNK-eIF4E signaling pathway in peripheral sensory neurons, aiming to provide effective pain relief without triggering the central nervous system effects that many existing medications do.
Joseph Price, the co-founder and president of 4E Therapeutics, expressed his enthusiasm regarding the acquisition, stating, "We founded 4E Therapeutics with a simple but ambitious goal: to create non-opioid therapies that directly address the neurological causes of pain. Lilly’s commitment to combating chronic pain, coupled with its vast resources and global reach, makes it the perfect partner to bring this vision to fruition."
The sentiment is echoed by Dr. Theodore Price, another co-founder of 4E Therapeutics and a distinguished figure in pain research. Commenting on the evolution of their scientific breakthroughs into viable treatments, he noted, "Witnessing our extensive research on the molecular mechanisms behind chronic pain transition from basic studies to clinical applications, now integrated within Lilly’s development pipeline, is a thrilling opportunity to expedite access to new therapies for patients." This highlights the synergy of their combined efforts to tackle the multifaceted challenges of chronic pain treatments.
Although the financial terms of this transaction remain undisclosed, the partnership is believed to be a valuable step forward for both companies. 4E Therapeutics was advised by Aquilo Partners LP during the acquisition process, while Wilson Sonsini Goodrich & Rosati provided legal support.
Founded on the principles of advanced neuroscience, 4E Therapeutics aims to redefine the landscape of pain management by developing non-addictive therapies. Their focus ranges across various pain-related conditions, such as neuropathic and acute pain, through groundbreaking mechanisms that seek to interrupt pain signaling at its core. The company’s journey in medicinal chemistry and drug development has been notably led by Vice President of Drug Development, James Sahn, while T. Craig Benson, a serial entrepreneur in biotechnology, has guided 4E from its inception as CEO.
With the acquisition now finalized, both Lilly and 4E Therapeutics are poised to harness their combined expertise and resources to expedite the development of innovative therapies, ultimately benefitting countless individuals grappling with chronic pain conditions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.